NoncoRNA: a Database of Experimentally Supported Non-coding RNAs and Drug Targets in Cancer

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2020 Mar 1

PMID 32111231

Citations 36

Authors

Lulu Li

Pengfei Wu

Zhenyu Wang

Xiangqi Meng

Caijun Zha

Ziwei Li

Tengfei Qi

Yangong Zhang

Bo Han

Shupeng Li

Chuanlu Jiang

Zheng Zhao

Jinquan Cai

Affiliations

Soon will be listed here.

Abstract

NoncoRNA (http://www.ncdtcdb.cn:8080/NoncoRNA/) is a manually curated database of experimentally supported non-coding RNAs (ncRNAs) and drug target associations that aim to potentially provide a high-quality data resource for exploring drug sensitivity/resistance-related ncRNAs in various human cancers. ncRNA are RNA molecular that do not encode proteins, but are involved in gene regulation and cellular functions in variety of human diseases, including neurodegenerative diseases and cancers. Here, we developed NoncoRNA which contained 8233 entries between 5568 ncRNAs and 154 drugs in 134 cancers. Each entry in the NoncoRNA contains detailed information on the ncRNAs, drugs, and cancers, the ncRNA expression pattern and experimental detection techniques, drug response and other targets, literature references, and other information. NoncoRNA offers a user-friendly, open access web interface to easily browse, search, and download data. NoncoRNA also provides a submission page for researchers to submit newly validated ncRNA-drug-cancer associations. NoncoRNA might serve as an immeasurable resource for understanding the roles of ncRNAs in cancer therapy.

Citing Articles

Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.

Marton E, Varga A, Domoszlai D, Buglyo G, Balazs A, Penyige A Cancers (Basel). 2025; 17(4).

PMID: 40002172 PMC: 11853212. DOI: 10.3390/cancers17040579.

The evolution and application of RNA-focused small molecule libraries.

Taghavi A, Springer N, Zanon P, Li Y, Li C, Childs-Disney J RSC Chem Biol. 2025; .

PMID: 39957993 PMC: 11824871. DOI: 10.1039/d4cb00272e.

Advances and Mechanisms of RNA-Ligand Interaction Predictions.

Zhuo C, Zeng C, Liu H, Wang H, Peng Y, Zhao Y Life (Basel). 2025; 15(1).

PMID: 39860045 PMC: 11767038. DOI: 10.3390/life15010104.

MDFGNN-SMMA: prediction of potential small molecule-miRNA associations based on multi-source data fusion and graph neural networks.

Li J, Zhang X, Li B, Li Z, Chen Z BMC Bioinformatics. 2025; 26(1):13.

PMID: 39806287 PMC: 11730471. DOI: 10.1186/s12859-025-06040-4.

LncRNA FAISL Inhibits Calpain 2-Mediated Proteolysis of FAK to Promote Progression and Metastasis of Triple Negative Breast Cancer.

Zhang Y, Wei S, Chen Z, Xu R, Li S, You L Adv Sci (Weinh). 2024; 11(42):e2407493.

PMID: 39287113 PMC: 11558121. DOI: 10.1002/advs.202407493.

References

Sang Y, Chen B, Song X, Li Y, Liang Y, Han D . circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther. 2019; 27(9):1638-1652. PMC: 6731174. DOI: 10.1016/j.ymthe.2019.05.011. View

Heilskov Rasmussen M, Lyskjaer I, Jersie-Christensen R, Tarpgaard L, Primdal-Bengtson B, Nielsen M . miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. Nat Commun. 2016; 7:12436. PMC: 4990699. DOI: 10.1038/ncomms12436. View

Mai D, Ding P, Tan L, Zhang J, Pan Z, Bai R . PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics. 2018; 8(19):5213-5230. PMC: 6276099. DOI: 10.7150/thno.28001. View

Malek E, Jagannathan S, Driscoll J . Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget. 2014; 5(18):8027-38. PMC: 4226665. DOI: 10.18632/oncotarget.2469. View

Sarkar F, Li Y, Wang Z, Kong D, Ali S . Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010; 13(3):57-66. PMC: 2883024. DOI: 10.1016/j.drup.2010.02.001. View